Consensus UCB

Stocks

UCB

BE0003739530

Pharmaceuticals

Real-time Euronext Bruxelles 05:31:44 21/09/2026 pm IST			5-day change	1st Jan Change
210.20 ^EUR	+1.01%		-0.14%	-11.90%

11/09	AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up	MT
10/09	UCB: A rare window of affordability

Evolution of the Average Target: UCB

Evolution of the Target Price: UCB

Changes in Analyst Recommendations: UCB

26f1cc.ZYiKGnFPcQFzziKtsjs1mvQ8cm_-il06BCbi3I_ncj4.KP7QThUcAUYHlm3Yg0xt0J5XRh-PuRxpfUOotNisM3AA3-hwPRkhajCocw~d20f8b4e3104e03ff2dd1216972c0188

Analysts' recommendations: UCB

11/09	AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up	MT
10/09	UCB: A rare window of affordability
20/08	Cancer vaccines finally garner the spotlight
18/08	UCB: An unimpressive upgrade-led correction opens a rare opportunity
11/08	Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed	MT
11/08	UCB barely moves despite positive calls from ING and Berenberg
31/07	AlphaValue/Baader Europe Upgrades UCB to Add, Trims PT	MT
30/07	Kempen Upgrades UCB to Buy Rating, Boosts PT	MT
14/07	Where would AI lead Pharma in the long run?
03/07	Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals	MT
22/06	UBS Trims UCB's PT, Affirms Buy Rating	MT
15/06	UCB Slumps Following Analyst Downgrade
15/06	Barclays Downgrades UCB to Equalweight, Trims PT	MT
15/06	UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum	MT
09/06	UCB Favored by Oddo BHF
05/06	KBC Securities Maintains Buy Rating on UCB
21/05	UCB Price Target, Estimates Up as AlphaValue/Baader Europe Notes Growth Momentum	MT
20/05	UCB: Executing well, but valuation lacks safety net
27/04	AlphaValue/Baader Europe Upgrades UCB to Reduce, Trims PT	MT
30/03	MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says	MT
16/03	Berenberg says Belgian drugmaker UCB stock is undervalued
16/03	Berenberg Keeps UCB Amid Positive Pipeline Progress, H2 Catalysts	MT
26/02	UCB: H2 beat; 2026 outlook healthy; but valuation remains red-hot
24/02	Wolfe Research Kicks Off UCB Coverage at Outperform	MT
02/02	UCB on Track for 'Impressive' Growth Acceleration, Says RBC	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	UCB					+36.95%
	REGENERON PHARMACEUTICALS, INC.					+8.21%
	MODERNA, INC.					-22.39%
	CSL LIMITED					+1.17%
	SAMSUNG BIOLOGICS CO.,LTD.					+40.74%
	BIOGEN INC.					+10.53%
	INCYTE CORPORATION					+1.94%
	INNOVENT BIOLOGICS, INC.					+33.64%
	SWEDISH ORPHAN BIOVITRUM AB					+12.06%
	BRIDGEBIO PHARMA, INC.					+63.78%
	Average					+18.66%
	Weighted average by Cap.					+12.63%